The critical importance of recognizing Gaucher disease in the fifth decade and beyond

For decades, the clinical management of Gaucher disease type 1 (GD1) in the Ashkenazi Jewish (AJ) population has been influenced by a persistent misconception: that patients homozygous for the founder variant p.N409S in the glucocerebrosidase-1 gene (GBA1), diagnosed in late adulthood (after 50 years of age), have a benign, non-progressive condition.

The groundbreaking retrospective case study, “Recognizing Gaucher disease in the fifth decade and beyond: a retrospective case study in patients of Ashkenazi Jewish descent”, by Stiles et al.^[1], published in the Rare Disease and Orphan Drugs Journal (RDODJ) volume 4, challenges this dogma, providing compelling evidence that diagnosis delayed beyond the fifth decade often masks severe, debilitating pathology.

The study examined 20 patients of AJ descent who were diagnosed with GD1 at age 50 or older, with a median age of 59 years. The clinical picture painted by this cohort is starkly at odds with the “asymptomatic” label often applied to this demographic. Upon diagnosis, 90% of these patients presented with splenomegaly, and 85% suffered from thrombocytopenia and osteopenia or osteoporosis. Perhaps most concerning is the skeletal burden: 70% of patients experienced bone or joint pain, and nearly half (45%) had already suffered pathological fractures. These are not features of a benign condition, but rather the accumulation of untreated pathology over decades.

Stiles et al.^[1] highlight a concerning “diagnostic odyssey” for these patients. Despite the high prevalence of Gaucher disease (GD) in the AJ population, diagnosis remains elusive; 60% of the cohort underwent invasive bone marrow biopsies to investigate cytopenia or fatigue before GD was identified. This underscores a critical gap in hematologic practice. GD should be a primary differential, not a diagnosis of exclusion found via biopsy. Furthermore, the intersection of GD and Parkinson’s disease (PD) cannot be ignored. In this cohort, 15% of patients were identified solely during a PD evaluation. Given the established link between GBA1 variants and parkinsonism, this study reinforces the necessity of including *GBA1* analysis in PD work-ups.

From a biomarker perspective, the study validates the utility of plasma glucosylsphingosine (lyso-Gb1). While chitotriosidase activity was normal in 20% of the cohort (rendering it a false negative in those cases), lyso-Gb1 was elevated in 100% of patients. This confirms lyso-Gb1 as the superior, highly sensitive biomarker for screening and diagnosis, even in patients with milder genotypes.

The implications of this study are immediate for clinicians treating older adults, particularly within the AJ community. The assumption that an older patient presenting with “mild” anemia or bone density loss is simply experiencing aging must be discarded in favor of a higher index of suspicion for GD1. With 15 of the 20 patients in this study requiring initiation of treatment due to significant disease burden, it is clear that late diagnosis is not a sign of mild disease but a missed opportunity for earlier intervention.

Stiles et al.^[1] have provided crucial new information. By maintaining clinical vigilance and utilizing sensitive biomarkers such as lyso-Gb1, physicians can prevent the unnecessary skeletal devastation and systemic complications that define the “hidden” burden of late-onset GD.